Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Plerixafor-moblized stem cells alone are capable of inducing early engraftment across the MHC-haploidentical canine barrier

Monica S. Thakar, Erlinda B. Santos, Simon Fricker, Gary Bridger, Rainer Storb, Brenda M. Sandmaier

Blood (2010) 115 (4): 916–917.

https://doi.org/10.1182/blood-2009-09-245696

Published: 2010

Journal Articles

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

Bruno Nervi, Pablo Ramirez, Michael P. Rettig, Geoffrey L. Uy, Matthew S. Holt, Julie K. Ritchey, Julie L. Prior, David Piwnica-Worms, Gary Bridger, Timothy J. Ley, John F. DiPersio

Blood (2009) 113 (24): 6206–6214.

https://doi.org/10.1182/blood-2008-06-162123

Published: 2009

Includes: Supplemental data

Journal Articles

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

John F. DiPersio, Edward A. Stadtmauer, Auayporn Nademanee, Ivana N. M. Micallef, Patrick J. Stiff, Jonathan L. Kaufman, Richard T. Maziarz, Chitra Hosing, Stefan Früehauf, Mitchell Horwitz, Dennis Cooper, Gary Bridger, Gary Calandra, for the 3102 Investigators

Blood (2009) 113 (23): 5720–5726.

https://doi.org/10.1182/blood-2008-08-174946

Published: 2009

Journal Articles

Months Report from the Phase 3 Study of Plerixafor+G-CSF VS. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with NHL.

John F. DiPersio, MD, PhD, Ivana NM Micallef, Patrick J. Stiff, MD, Brian J. Bolwell, MD, Richard Thomas Maziarz, MD, Gary Bridger, PhD, Gary Calandra, MD, PhD

Blood (2008) 112 (11): 1136.

https://doi.org/10.1182/blood.V112.11.1136.1136

Published: 2008

Journal Articles

12 Months Report from a Phase 3 Study of Plerixafor+G-CSF Vs. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with Multiple Myeloma

John F. DiPersio, MD, PhD, Edward A. Stadtmauer, MD, Auayporn P. Nademanee, Ivana NM Micallef, MD, Patrick J. Stiff, MD, Gary Bridger, PhD, Gary Calandra, MD, PhD

Blood (2008) 112 (11): 3312.

https://doi.org/10.1182/blood.V112.11.3312.3312

Published: 2008

Journal Articles

Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma.

Patrick J. Stiff, MD, Ivana NM Micallef, Auayporn P. Nademanee, Edward A. Stadtmauer, MD, Richard Thomas Maziarz, MD, Brian J. Bolwell, MD, Gary Bridger, PhD, Gary Calandra, MD, PhD, Jennifer Angell, MS, John F. DiPersio, MD, PhD

Blood (2008) 112 (11): 2175.

https://doi.org/10.1182/blood.V112.11.2175.2175

Published: 2008

Journal Articles

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction

Steven M. Devine, Ravi Vij, Michael Rettig, Laura Todt, Kiley McGlauchlen, Nicholas Fisher, Hollie Devine, Daniel C. Link, Gary Calandra, Gary Bridger, Peter Westervelt, John F. DiPersio

Blood (2008) 112 (4): 990–998.

https://doi.org/10.1182/blood-2007-12-130179

Published: 2008

Journal Articles

Successful Stem Cell Mobilization Rescue by AMD3100 (Plerixafor)+G-CSF for Patients Who Failed Primary Mobilization: Results from the Phase III (3101-NHL) Study.

Ivana Micallef, MD, Patrick J. Stiff, MD, John F. DiPersio, MD, PhD, Richard Thomas Maziarz, MD, John M. McCarty, MD, Jennifer Angell, MS, Gary Bridger, PhD, Gary Calandra, MD, on behalf of the 3101 Investigators7

Blood (2007) 110 (11): 602.

https://doi.org/10.1182/blood.V110.11.602.602

Published: 2007

Journal Articles

Massive Mobilization of AML Cells into Circulation by Disruption of Leukemia/Stroma Cell Interactions Using CXCR4 Antagonist AMD3100: First Evidence in Patients and Potential for Abolishing Bone Marrow Microenvironment-Mediated Resistance.

Michael Andreeff, MD, PhD, Sergej Konoplev, M.D., Ph.D., Rui-Yu Wang, M.D., Ph.D., Zhihong Zeng, Ph.D., Teresa McQueen, Yue-Xi Shi, L. Jeffrey Medeiros, M.D., Elihu Estey, M.D., John M. McCarty, M.D., Stephanie Elkins, M.D., Richard Champlin, M.D., Gary Calandra, M.D., Ph.D., Gary Bridger, Ph.D., Marina Konopleva, M.D., Ph.D.

Blood (2006) 108 (11): 568.

https://doi.org/10.1182/blood.V108.11.568.568

Published: 2006

Journal Articles

CXCR4/SDF-1 Is a Key Regulator for Leukemia Migration and Homing to the BM: Impact of AMD3100 on In Vivo Response to Chemotherapy.

Bruno Nervi, MD, Pablo Ramirez, MD, Matthew Holt, Michael P. Rettig, PhD, Julie K. Ritchey, Julie L. Prior, David Piwnica-Worms, MD,PhD, Gary Bridger, PhD, Timothy J. Ley, MD,PhD, John F. DiPersio, MD,PhD

Blood (2006) 108 (11): 569.

https://doi.org/10.1182/blood.V108.11.569.569

Published: 2006

Journal Articles

HLA-Matched Sibling Donor Stem Cell Mobilization Can Be Safely and Effectively Reduced from a Five Day to a One Day Process by a Direct Antagonist of the CXCR4/SDF-1 Interaction.

Steven M. Devine, MD, Ravi Vij, MD, Laura Todt, RN, Kiley McLaughlin, BS, Nicholas Fisher, BA, Natalie Morris, Daniel C. Link, MD, Gary Calandra, MD, Gary Bridger, PhD, John F. DiPersio, MD, PhD

Blood (2006) 108 (11): 53.

https://doi.org/10.1182/blood.V108.11.53.53

Published: 2006

Journal Articles

The CXCR4 Antagonist AMD3100 and the CXCR2 Agonist GROβ Synergistically Mobilize Hematopoetic Stem Cells (HSC) with Short and Long Term Repopulating Activity.

Louis M. Pelus, PhD, Seiji Fukuda, MD, PhD, Gary Bridger, PhD

Blood (2006) 108 (11): 339.

https://doi.org/10.1182/blood.V108.11.339.339

Published: 2006

Journal Articles

Suprasynergistic Peripheral Blood Stem Cell Mobilization in Normal and Fanconi Anemia Knockout Mice by the Combination of G-CSF Plus the CXCR4 Antagonist AMD3100 and the CXCR2 Agonist GRO β

Louis M. Pelus, PhD, D. Wade Clapp, MD, Gary Bridger, PhD

Blood (2006) 108 (11): 3185.

https://doi.org/10.1182/blood.V108.11.3185.3185

Published: 2006

Journal Articles

Mobilization as a preparative regimen for hematopoietic stem cell transplantation

Jing Chen, André Larochelle, Simon Fricker, Gary Bridger, Cynthia E. Dunbar, Janis L. Abkowitz

Blood (2006) 107 (9): 3764–3771.

https://doi.org/10.1182/blood-2005-09-3593

Published: 2006

Journal Articles

AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates

André Larochelle, Allen Krouse, Mark Metzger, Donald Orlic, Robert E. Donahue, Simon Fricker, Gary Bridger, Cynthia E. Dunbar, Peiman Hematti

Blood (2006) 107 (9): 3772–3778.

https://doi.org/10.1182/blood-2005-09-3592

Published: 2006

Journal Articles

Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model

Lauri Burroughs, Marco Mielcarek, Marie-Térèse Little, Gary Bridger, Ron MacFarland, Simon Fricker, Jean Labrecque, Brenda M. Sandmaier, Rainer Storb

Blood (2005) 106 (12): 4002–4008.

https://doi.org/10.1182/blood-2005-05-1937

Published: 2005

Journal Articles

The CXCR4 Antagonist AMD3100 Mobilizes a More Primitive Subset of CD34+ Cells Than G-CSF.

Timon Seeger, Marlon Veldwijk, PhD, Gary Bridger, PhD, Gary Calandra, MD, PhD, Hartmut Goldschmidt, MD, Anthony Ho, MD, Stefan Fruehauf, MD

Blood (2005) 106 (11): 1969.

https://doi.org/10.1182/blood.V106.11.1969.1969

Published: 2005

Journal Articles

Kinetics of Hematopoietic Progenitor Cell Mobilization with Cyclophosphamide or Cyclophosphamide Plus AMD3100 Using a Mouse Model.

Bill Q. Gai, MD, PhD, Matthew S. Holt, Bruno Nervi, MD, Michael P. Rettig, PhD, Julie K. Ritchey, Gary Bridger, PhD, John F. DiPersio, MD, PhD

Blood (2005) 106 (11): 5217.

https://doi.org/10.1182/blood.V106.11.5217.5217

Published: 2005

Journal Articles

Evaluation of the Phenotype and GVHD-Inducing Potential of Splenic T Cells Isolated from G-CSF, AMD3100, or G-CSF and AMD3100 Pretreated Allogeneic Donors.

Michael Rettig, PhD, Matthew Holt, Fulu Liu, MD, Julie Ritchey, Daniel Link, MD, Gary Bridger, PhD, John DiPersio, MD/PhD

Blood (2005) 106 (11): 5224.

https://doi.org/10.1182/blood.V106.11.5224.5224

Published: 2005

Journal Articles

A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies.

Steven M. Devine, MD, Leslie Andritsos, MD, Laura Todt, Ravi Vij, MD, Jesper Bonde, PhD, David Hess, PhD, Jan Nolta, PhD, Dan Link, MD, Gary Bridger, PhD, Gary Calandra, MD, John F. DiPersio, MD, PhD

Blood (2005) 106 (11): 299.

https://doi.org/10.1182/blood.V106.11.299.299

Published: 2005

NARROW

Plerixafor-moblized stem cells alone are capable of inducing early engraftment across the MHC-haploidentical canine barrier

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

Months Report from the Phase 3 Study of Plerixafor+G-CSF VS. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with NHL.

12 Months Report from a Phase 3 Study of Plerixafor+G-CSF Vs. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with Multiple Myeloma

Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma.

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction

Successful Stem Cell Mobilization Rescue by AMD3100 (Plerixafor)+G-CSF for Patients Who Failed Primary Mobilization: Results from the Phase III (3101-NHL) Study.

Massive Mobilization of AML Cells into Circulation by Disruption of Leukemia/Stroma Cell Interactions Using CXCR4 Antagonist AMD3100: First Evidence in Patients and Potential for Abolishing Bone Marrow Microenvironment-Mediated Resistance.

CXCR4/SDF-1 Is a Key Regulator for Leukemia Migration and Homing to the BM: Impact of AMD3100 on In Vivo Response to Chemotherapy.

HLA-Matched Sibling Donor Stem Cell Mobilization Can Be Safely and Effectively Reduced from a Five Day to a One Day Process by a Direct Antagonist of the CXCR4/SDF-1 Interaction.

The CXCR4 Antagonist AMD3100 and the CXCR2 Agonist GROβ Synergistically Mobilize Hematopoetic Stem Cells (HSC) with Short and Long Term Repopulating Activity.

Suprasynergistic Peripheral Blood Stem Cell Mobilization in Normal and Fanconi Anemia Knockout Mice by the Combination of G-CSF Plus the CXCR4 Antagonist AMD3100 and the CXCR2 Agonist GRO β

Mobilization as a preparative regimen for hematopoietic stem cell transplantation

AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates

Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model

The CXCR4 Antagonist AMD3100 Mobilizes a More Primitive Subset of CD34+ Cells Than G-CSF.

Kinetics of Hematopoietic Progenitor Cell Mobilization with Cyclophosphamide or Cyclophosphamide Plus AMD3100 Using a Mouse Model.

Evaluation of the Phenotype and GVHD-Inducing Potential of Splenic T Cells Isolated from G-CSF, AMD3100, or G-CSF and AMD3100 Pretreated Allogeneic Donors.

A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only